Compounds > celecoxib
Page last updated: 2024-10-24

celecoxib and Arteriosclerosis, Coronary

celecoxib has been researched along with Arteriosclerosis, Coronary in 8 studies

Research Excerpts

ExcerptRelevanceReference
" We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia."9.16Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents. ( Choi, D; Hong, MK; Jang, Y; Kang, KW; Kim, BK; Kim, JS; Kim, WH; Ko, YG, 2012)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."7.83Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months."5.24Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) ( Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017)
" We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia."5.16Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents. ( Choi, D; Hong, MK; Jang, Y; Kang, KW; Kim, BK; Kim, JS; Kim, WH; Ko, YG, 2012)
"The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)."3.83Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016)
"This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease."3.77Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011)
" Naproxen users had the lowest adjusted rates of serious coronary heart disease (myocardial infarction, coronary heart disease death) and serious cardiovascular disease (myocardial infarction, stroke)/death from any cause, with respective incidence rate ratios (relative to NSAID nonusers) of 0."3.75Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. ( Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C, 2009)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ruschitzka, F2
Borer, JS1
Krum, H1
Flammer, AJ1
Yeomans, ND1
Libby, P1
Lüscher, TF2
Solomon, DH1
Husni, ME1
Graham, DY1
Davey, DA1
Wisniewski, LM1
Menon, V1
Fayyad, R1
Beckerman, B1
Iorga, D1
Lincoff, AM1
Nissen, SE1
Wu, LC1
Leong, PY1
Yeo, KJ1
Li, TY1
Wang, YH1
Chiou, JY1
Wei, JC1
Ray, WA1
Varas-Lorenzo, C1
Chung, CP1
Castellsague, J1
Murray, KT1
Stein, CM1
Daugherty, JR1
Arbogast, PG1
García-Rodríguez, LA1
Bavry, AA1
Khaliq, A1
Gong, Y1
Handberg, EM1
Cooper-Dehoff, RM1
Pepine, CJ1
Kim, WH1
Ko, YG1
Kang, KW1
Kim, JS1
Kim, BK1
Choi, D1
Hong, MK1
Jang, Y1
Chenevard, R1
Hürlimann, D1
Béchir, M1
Enseleit, F1
Spieker, L1
Hermann, M1
Riesen, W1
Gay, S1
Gay, RE1
Neidhart, M1
Michel, B1
Noll, G1
Schultz, O1
Buttgereit, F1
Bangalore, S1
Khianey, S1
Messerli, FH1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216]Phase 424,081 participants (Actual)Interventional2006-10-04Completed
A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073]Phase 2/Phase 384 participants (Actual)Interventional2017-04-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months

,,
InterventionNumber of participants (Mean)
Baseline (ITT) N= 8014, 8001, 7928Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439Baseline (MITT) N=7974, 7954, 7894Change-Baseline to Mon1 MITT N=7372, 7367, 7321Change-Baseline to Mon2 MITT N=7170, 7078, 7142Change-Baseline to Mon4 MITT N=6772, 6686, 6732Change-Baseline to Mon8 MITT N=6224, 6128, 6155Change-Baseline to Mon12 MITT N=5787, 5689, 5844Change-Baseline to Mon18 MITT N=5305, 5175, 5242Change-Baseline to Mon24 MITT N=4815, 4769, 4782Change-Baseline to Mon30 MITT N=4139, 4067, 4085Change-Baseline to Mon36 MITT N=3691, 3623, 3635Change-Baseline to Mon42 MITT N=3468, 3404, 3438
Celecoxib54.0-8.2-10.5-11.4-11.7-11.0-11.3-11.3-10.5-10.1-11.454.0-8.2-10.5-11.4-11.7-11.0-11.3-11.4-10.5-10.2-11.4
Ibuprofen54.1-9.0-10.6-11.7-12.1-11.6-11.3-11.5-11.2-10.7-11.154.1-9.0-10.6-11.7-12.1-11.6-11.3-11.5-11.2-10.7-11.1
Naproxen54.1-9.9-11.1-12.3-12.1-11.9-11.7-11.4-11.3-11.6-12.154.1-9.9-11.1-12.3-12.1-11.9-11.7-11.3-11.3-11.6-12.1

The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

,,
InterventionPercentage of Participants (Number)
ITT (N = 8072, 8040, 7969)MITT (N = 8030, 7990, 7933)
Celecoxib4.23.1
Ibuprofen4.83.6
Naproxen4.33.2

The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months

,,
InterventionPercentage of Partcipants (Number)
ITT (N = 8072, 8040, 7969)MITT (N = 8030, 7990, 7933)
Celecoxib2.31.7
Ibuprofen2.71.9
Naproxen2.51.8

The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

,,
InterventionPercentage of Participants (Number)
ITT (N = 8072, 8040, 7969)MITT (N = 8030, 7990, 7933)
Celecoxib0.70.3
Ibuprofen0.90.7
Naproxen0.70.7

Trials

4 trials available for celecoxib and Arteriosclerosis, Coronary

ArticleYear
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
    European heart journal, 2017, Nov-21, Volume: 38, Issue:44

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary

2017
Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents.
    Yonsei medical journal, 2012, Volume: 53, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Biomarkers; Celecoxib; Coronary Artery

2012
Selective COX-2 inhibition improves endothelial function in coronary artery disease.
    Circulation, 2003, Jan-28, Volume: 107, Issue:3

    Topics: Aged; Biomarkers; C-Reactive Protein; Celecoxib; Coronary Artery Disease; Cross-Over Studies; Cycloo

2003
[Selective COX-2 inhibition improves endothelial function in coronary artery disease].
    Zeitschrift fur Rheumatologie, 2003, Volume: 62, Issue:4

    Topics: Aged; Arteries; Celecoxib; Coronary Artery Disease; Coronary Vessels; Cyclooxygenase 2; Endothelium-

2003

Other Studies

4 other studies available for celecoxib and Arteriosclerosis, Coronary

ArticleYear
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
    Medicine, 2016, Volume: 95, Issue:36

    Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis

2016
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:3

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; C

2009
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
    The American journal of medicine, 2011, Volume: 124, Issue:7

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec

2011
Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial.
    The American journal of cardiology, 2008, Apr-01, Volume: 101, Issue:7

    Topics: Angioplasty, Balloon, Coronary; Blood Pressure; Celecoxib; Coronary Artery Disease; Coronary Resteno

2008